News

FDA needs additional information before approval of ABBV-951

The U.S. Food and Drug Administration (FDA) has requested more information about the specialized pump used to administer ABBV-951 (foslevodopa/foscarbidopa), an under-the-skin formulation of levodopa/carbidopa, before it will consider approving the therapy for motor fluctuations in people with advanced Parkinson’s disease. The agency’s complete response letter comes 10…

Gains seen in Parkinson’s with Symbyx’s red light therapy helmet

Symbyx Neuro, Symbyx Biome’s red/infrared light therapy helmet, improves motor function in Parkinson’s disease, according to data from a small sham-controlled clinical trial. Parkinson’s “has historically been an intractable, neurodegenerative condition that typically declines with no improvements possible,” Wayne Markman, Symbyx‘s CEO, said in a company…

Ban sought for TCE, common chemical likely linked to Parkinson’s

Scientists are calling for a ban on trichloroethylene (TCE), a common and widely used chemical that’s increasingly linked to multiple health problems, including cancer and Parkinson’s disease. “Through a literature review and seven illustrative cases, we postulate that this ubiquitous chemical is contributing to the global rise of PD…

Student creates Parkinson’s app that monitors falls

Interface Systems has awarded Northwestern University student Laura Felix a $5,000 “Tech for Good” scholarship for creating an app that helps caregivers manage falls by Parkinson’s disease patients. Felix is studying computer science and physics at the university and the one-time scholarship is for the 2022-2023 academic year. Interface also…

Older adults sought for Smell Test Challenge

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is calling on adults 60 and older in the U.S. and Canada who do not have Parkinson’s disease to participate in the Smell Test Challenge, which aims to better understand the connection between loss of smell and neurological disease.